Advertisement

Clinical Oral Investigations

, Volume 22, Issue 8, pp 2953–2955 | Cite as

Coexistence of oral lichen planus and pemphigus vulgaris

  • Kamran Balighi
  • HamidReza Mahmoudi
  • Soheil Tavakolpour
  • Maryam Daneshpazhooh
Letter to the Editor
  • 96 Downloads

Dear Editor,

Over the past decades, several cases regarding the coexistence of two mucosal/skin-related autoimmune/inflammatory conditions have been reported. One of the least reported is the coexistence of pemphigus vulgaris (PV) and lichen planus (LP). Regardless of a few reports of coexistence of oral LP (OLP) or generalized LP with PV, which had been published more than two decades ago, none has been reported in the recent years [ 1, 2]. As a brief survey in registered cases of PV in Razi Hospital, Tehran University of Medical Sciences, we have focused on two patients affected with this coexistence. Both patients had a clinical and histopathological diagnosis of PV. Additionally, they had positive intercellular direct immunofluorescence and detectable autoantibodies against the desmoglein (Dsg)1 and/or Dsg3 at the beginning of their disease. Years after diagnosis of PV, OLP has been manifested in these patients. In contrast to their PV, which responded to conventional treatments,...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Neumann-Jensen B, Worsaae N, Dabelsteen E, Ullman S (1980) Pemphigus vulgaris and pemphigus foliaceus coexisting with oral lichen planus. Br J Dermatol 102:585–590CrossRefGoogle Scholar
  2. 2.
    Lee CW, Hur H, Youn JI (1987) Pemphigus vulgaris coexisting with generalized lichen planus. J Dermatol 14:388–391CrossRefGoogle Scholar
  3. 3.
    Vahide L, Zahra H, Forugh G, Nazi S (2017) Autoantibodies to desmogleins 1 and 3 in patients with lichen planus. Arch Dermatol Res 309:579–583.  https://doi.org/10.1007/s00403-017-1756-x CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Schmidt T, Solimani F, Pollmann R, Stein R, Schmidt A, Stulberg I, Kuhn K, Eming R, Eubel V, Kind P, Arweiler N, Sitaru C, Hertl M (2018) TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. J Allergy Clin Immunol 142:669–672.e7.  https://doi.org/10.1016/j.jaci.2018.02.044 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M (2018) Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol 54:131–138.  https://doi.org/10.1016/j.intimp.2017.11.005 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Heelan K, McAleer MA, Roche L, McCreary C, Murphy M (2015) Intractable erosive lichen planus treated successfully with rituximab. Br J Dermatol 172:538–540.  https://doi.org/10.1111/bjd.13537 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Kamran Balighi
    • 1
  • HamidReza Mahmoudi
    • 1
  • Soheil Tavakolpour
    • 1
  • Maryam Daneshpazhooh
    • 1
  1. 1.Autoimmune Bullous Diseases Research Center, Razi HospitalTehran University of Medical SciencesTehranIran

Personalised recommendations